NTRA

Natera Inc

328.93

Sep 11 • 3:59 PM ET +2.79 (0.86%)

328.93

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Large NASD

Peers: IQV LH ICLR IDXX A DHR TMO WAT MTD BIO

| Held by: VTI VB VBK VXF IBB IWP IWR IWF IWF XBI

Scroll to Statements

Index	-
Market Cap	47.41B
Enterprise Value	46.56B
Income	-192.35M
Sales	2.71B
Book/sh	12.68
Cash/sh	7.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6140
IPO	Jul 02, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	17.51
P/B	25.93
P/C	43.44
P/FCF	563.10
EV/EBITDA	-
EV/Sales	17.20
Quick Ratio	2.85
Current Ratio	3.00
Debt/Eq	0.13
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-1.37
EPS next Y	-0.13
EPS next Q	-0.22
EPS this Y	11.35%
EPS next Y	90.04%
EPS next 5Y	-
EPS past 3/5Y	35.09% 11.70%
Sales past 3/5Y	41.14% 42.61%
EPS Y/Y TTM	28.02%
Sales Y/Y TTM	37.82%
EPS Q/Q	36.85%
Sales Q/Q	37.71%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	4.84% 13.84%

Insider Own	6.56%
Insider Trans	-6.86%
Inst Own	92.55%
Inst Trans	1.40%
ROA	-8.71%
ROE	-12.54%
ROIC	-9.79%
Gross Margin	64.74%
Oper. Margin	-10.56%
Profit Margin	-7.11%
SMA20	0.92%
SMA50	10.82%
SMA200	38.35%
Trades

Shs Outstand	143.61M
Shs Float	134.69M
Short Float	4.09%
Short Ratio	4.01
Short Interest	5.51M
52W High	343.18 -4.15%
52W Low	157.43 108.94%
Volatility	2.66% 3.15%
ATR (14)	10.72
RSI (14)	60.12
Beta	1.53
Rel Volume	0.58
Avg Volume	1.38M
Volume	798,060

Perf Week	0.38%
Perf Month	4.10%
Perf Quarter	50.04%
Perf Half Y	72.84%
Perf YTD	43.58%
Perf Year	89.25%
Perf 3Y	502.55%
Perf 5Y	173.77%
Perf 10Y	3189.30%
Recom	1.46
Target Price	344.33
Prev Close	326.14
Price	328.93
Change %	0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Resumed	UBS	Buy	$435
Sep-08-26	Initiated	Rothschild & Co Redburn	Buy	$385
Jun-26-26	Resumed	Bernstein	Outperform	$310
Jun-12-26	Resumed	RBC Capital Mkts	Outperform	$275
Jun-02-26	Resumed	Wolfe Research	Outperform	$260
Apr-14-26	Initiated	William Blair	Outperform
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48

Show Previous Ratings

Sep-01-26 06:00AM	New Publication Establishes Strong Clinical Validation of Signatera for MRD Assessment in Lymphoma (Business Wire)
Aug-28-26 11:03AM	Natera and Susan G. Komen Announce National Partnership to Accelerate Progress Against Breast Cancer (Business Wire)
Aug-24-26 02:23PM	What Is Really Moving Tempus AI Stock Right Now? (Trefis)
Aug-17-26 11:55AM	13F Season: Where Wall Street's Smart Money is Betting (Zacks)
Aug-14-26 06:05PM	Stanley Druckenmiller's Bold Second Quarter 2026 Move: Slashing Alcoa Corp at a -2. ... (GuruFocus.com)
06:00AM	Loading…
Aug-12-26 06:00AM	Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude in Advanced Skin Cancers (Business Wire)
Aug-07-26 01:55PM	These Two Biotech Stocks Hit Fresh 52-Week Highs Today NTRA Clocks Best Day In Nearly 20 Months (Stocktwits) +21.37%
10:42AM	SpaceX's influence ripples across markets: AlphaCheck (Yahoo Finance)
08:30AM	Natera, Inc. Q2 2026 Earnings Call Summary (Moby)
01:09AM	Natera Inc (NTRA) (Q2 2026) Earnings Call Highlights: Record Volumes and Raised Guidance Signal ... (GuruFocus.com)
Aug-06-26 05:30PM	Natera: Q2 Earnings Snapshot (Associated Press)
Aug-05-26 06:00AM	Natera Submits Signatera to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (Business Wire)
Aug-03-26 04:06PM	Buffett-Inspired ETF Owns Berkshire, Apple, Amex and Generates 15% Yield (Barrons.com)
Jul-30-26 08:00AM	Natera to Report its Second Quarter Results on August 6, 2026 (Business Wire) +6.24%
Jul-22-26 06:00AM	Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study (Business Wire)
12:06PM	Loading…
Jul-20-26 12:06PM	Cathie Wood Dumps $39 Million Worth of AMD Stock (GuruFocus.com)
Jul-16-26 06:35PM	Finalized MolDx LCD Includes Expanded Coverage for Nateras Prospera Portfolio (Business Wire)
08:13AM	Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It's Entering the U.S. (TSXV: SEGN) (FinanceWire)
Jul-13-26 12:52PM	Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group (GuruFocus.com)
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com)
Jul-09-26 06:00AM	Natera Announces IVDR Certification for Signatera Across Multiple Cancers (Business Wire)
Jul-06-26 06:00AM	Signatera MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer (Business Wire)
Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jul-01-26 06:02PM	When Multi-Cancer Blood Screens Could Finally Take Off (Barrons.com)
05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-29-26 06:00AM	Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer (Business Wire)
Jun-25-26 07:00AM	Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial (Business Wire)
Jun-24-26 05:00AM	Signatera Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire) +10.74%
Jun-23-26 06:00AM	NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update (Business Wire)
Jun-18-26 06:00AM	Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress (Business Wire)
10:40AM	Loading…
Jun-05-26 10:40AM	Healthcare Stocks Can Benefit From AI, Too. But That Isn't the Reason to Buy Them. (Barrons.com)
09:36AM	Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls (The Fly)
Jun-04-26 08:00AM	Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer (Business Wire)
Jun-03-26 08:00AM	Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors (Business Wire)
May-29-26 06:00AM	Natera Announces Collaboration with Diakonos Oncology for Signatera in Refractory Melanoma (Business Wire)
May-28-26 06:00AM	Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer (Business Wire) +5.33%
May-26-26 06:00AM	Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology (Business Wire)
May-21-26 05:05PM	Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology (Business Wire)
07:00AM	Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World (Business Wire)
May-20-26 04:51PM	Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder (IPO-Edge.com)
07:00AM	EXPAND Trial of Nateras Fetal Focus Single-Gene NIPT Surpasses >2,000 Patients Enrolled (Business Wire)
May-15-26 05:18PM	Stanley Druckenmiller Exits State Street Financial Select Sector SPDR ETF, Impacting Portfolio ... (GuruFocus.com) -5.36%
12:45PM	Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) (Business Wire)
12:01AM	Nateras Stronghold in Cancer Recurrence Tests Prompts Woods Ark to Expand Stake (The Daily Upside)
May-14-26 05:30AM	The Cancer Test That Wall Street Is Betting On (The Wall Street Journal)
May-07-26 05:22PM	Natera: Q1 Earnings Snapshot (Associated Press) -11.64%
04:05PM	Natera Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
Apr-30-26 08:00AM	Natera to Report its First Quarter Results on May 7, 2026 (Business Wire) +5.86%
Apr-23-26 12:33PM	SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases (Exec Edge)
Apr-22-26 09:00AM	Prospera Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT (Business Wire)
Apr-13-26 08:00AM	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma (Business Wire)
Apr-09-26 06:00AM	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents (Business Wire)
Apr-07-26 06:00AM	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform (Business Wire)
Mar-31-26 06:00AM	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery (Business Wire) +7.04%
Mar-16-26 06:00AM	Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers (Business Wire) +5.23%
Mar-12-26 08:00AM	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis (Business Wire)
08:00AM	MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 (PR Newswire)
Mar-09-26 12:41AM	3 Healthcare Stocks to Target This Week (StockStory)
Mar-04-26 07:10AM	Signatera Oncology Test Drives Natera's (NTRA) Growth (Insider Monkey)
Mar-03-26 03:35PM	Natera (NTRA) Stock Trades Up, Here Is Why (StockStory)
Feb-27-26 12:40PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
10:05AM	Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Business Wire)
08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:07AM	Natera Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... (GuruFocus.com)
Feb-26-26 11:53PM	Natera, Inc. (NTRA) Announces Results From the SINERGY Trial (Insider Monkey)
06:45PM	Natera (NTRA) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:30PM	Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:58PM	Natera: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 10:28PM	Natera Earnings: What To Look For From NTRA (StockStory)
06:00AM	Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer (Business Wire)
Feb-23-26 09:15AM	Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat)
08:10AM	Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Feb-17-26 04:01PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at State Street Financial Select Sector ... (GuruFocus.com)
09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 (Business Wire)
Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

CEOStephen Leonard Chapman

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 11 '26	Sale	327.97	50,000	16,398,267	2,225,394	Sep 11 09:35 PM
MATTHEW RABINOWITZ	Director	Sep 11 '26	Proposed Sale	326.14	200,000	65,228,000		Sep 11 04:28 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Sep 02 '26	Sale	326.89	15,160	4,955,713	110,859	Sep 03 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Sep 01 '26	Sale	320.73	3,000	962,194	126,019	Sep 03 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 01 '26	Sale	320.99	1,698	545,041	98,199	Sep 03 09:05 PM
STEVEN L CHAPMAN	Officer	Sep 01 '26	Proposed Sale	320.99	1,698	545,041		Sep 01 04:08 PM
SOLOMON MOSHKEVICH	Officer	Sep 01 '26	Proposed Sale	320.73	3,000	962,194		Sep 01 04:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 10 '26	Sale	321.53	6,517	2,095,411	197,257	Aug 28 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 10 '26	Sale	325.32	6,000	1,951,942	230,464	Aug 14 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 07 '26	Sale	320.90	2,000	641,800	2,000	Aug 07 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 07 '26	Sale	315.66	9,150	2,888,325	236,464	Aug 07 09:35 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Aug 07 '26	Proposed Sale	320.90	2,000	641,800		Aug 07 05:42 PM
Sheena Jonathan	Director	Aug 07 '26	Proposed Sale	330.62	18,000	5,951,100		Aug 07 10:41 AM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Aug 04 '26	Sale	274.22	478	131,077	51,637	Aug 05 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Aug 03 '26	Sale	267.99	317	84,953	52,115	Aug 05 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 03 '26	Sale	266.39	3,076	819,431	99,897	Aug 05 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 03 '26	Sale	267.99	295	79,057	183,774	Aug 05 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Aug 03 '26	Sale	265.58	3,410	905,627	129,019	Aug 05 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Aug 03 '26	Sale	267.99	334	89,508	170,073	Aug 05 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 03 '26	Sale	267.99	731	195,900	2,275,394	Aug 05 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 03 '26	Sale	267.99	109	29,211	245,614	Aug 05 09:35 PM
MICHAEL BROPHY	Officer	Aug 04 '26	Proposed Sale	270.36	478	129,232		Aug 04 04:36 PM
JONATHAN SHEENA	OFFICER	Aug 03 '26	Proposed Sale	267.76	108	28,918		Aug 03 04:22 PM
MATTHEW RABINOWITZ	OFFICER	Aug 03 '26	Proposed Sale	267.76	722	193,323		Aug 03 04:22 PM
DANIEL RABINOWITZ	OFFICER	Aug 03 '26	Proposed Sale	267.76	330	88,361		Aug 03 04:22 PM
SOLOMON MOSHKEVICH	OFFICER	Aug 03 '26	Proposed Sale	267.76	405	108,443		Aug 03 04:21 PM
JOHN FESKO	OFFICER	Aug 03 '26	Proposed Sale	267.76	292	78,186		Aug 03 04:21 PM
STEVEN CHAPMAN	OFFICER	Aug 03 '26	Proposed Sale	267.76	1,167	312,476		Aug 03 04:21 PM
MICHAEL BROPHY	OFFICER	Aug 03 '26	Proposed Sale	267.76	313	83,809		Aug 03 04:20 PM
STEVEN L CHAPMAN	Officer	Aug 03 '26	Proposed Sale	265.40	1,894	502,668		Aug 03 04:18 PM
SOLOMON MOSHKEVICH	Officer	Aug 03 '26	Proposed Sale	265.25	3,000	795,751		Aug 03 04:09 PM
Sheena Jonathan	CO-FOUNDER	Jul 27 '26	Sale	260.49	288	75,021	245,914	Jul 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jul 28 '26	Sale	254.07	191	48,527	245,723	Jul 29 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jul 27 '26	Sale	260.49	1,718	447,523	2,276,125	Jul 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 28 '26	Sale	254.07	1,003	254,833	170,407	Jul 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 27 '26	Sale	260.49	884	230,274	171,410	Jul 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 28 '26	Sale	254.07	1,204	305,901	132,429	Jul 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 27 '26	Sale	260.49	1,010	263,096	133,633	Jul 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 28 '26	Sale	254.07	931	236,540	184,069	Jul 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 27 '26	Sale	260.49	782	203,704	185,000	Jul 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 28 '26	Sale	254.07	3,580	909,572	102,973	Jul 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 27 '26	Sale	260.49	2,190	570,475	106,553	Jul 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 28 '26	Sale	253.96	2,419	614,336	54,295	Jul 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 29 '26	Sale	249.38	1,863	464,595	52,432	Jul 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 27 '26	Sale	260.49	782	203,704	56,714	Jul 29 09:35 PM
MICHAEL BROPHY	Officer	Jul 29 '26	Proposed Sale	252.22	1,863	469,886		Jul 29 04:21 PM
MICHAEL BROPHY	Officer	Jul 28 '26	Proposed Sale	258.03	1,178	303,959		Jul 28 04:40 PM
JONATHAN SHEENA	DIRECTOR	Jul 28 '26	Proposed Sale	258.03	188	48,510		Jul 28 04:08 PM
DANIEL RABINOWITZ	OFFICER	Jul 28 '26	Proposed Sale	258.03	988	254,934		Jul 28 04:08 PM
SOLOMON MOSHKEVICH	OFFICER	Jul 28 '26	Proposed Sale	258.03	1,185	305,766		Jul 28 04:08 PM
JOH N FESKO	OFFICER	Jul 28 '26	Proposed Sale	258.03	917	236,614		Jul 28 04:08 PM
STEVEN CHAPMAN	OFFICER	Jul 28 '26	Proposed Sale	258.03	3,525	909,556		Jul 28 04:07 PM
MICHAEL BROPHY	OFFICER	Jul 28 '26	Proposed Sale	258.03	1,222	315,313		Jul 28 04:07 PM
JONATHAN SHEENA	DIRECTOR	Jul 27 '26	Proposed Sale	261.99	285	74,667		Jul 27 03:36 PM
MATTHEW RABINOWITZ	DIRECTOR	Jul 27 '26	Proposed Sale	261.99	1,697	444,597		Jul 27 03:36 PM
DANIEL RABINOWITZ	OFFICER	Jul 27 '26	Proposed Sale	261.99	873	228,717		Jul 27 03:36 PM
SOLOMON MOSHKEVICH	OFFICER	Jul 27 '26	Proposed Sale	261.99	998	261,466		Jul 27 03:36 PM
JOHN FESKO	OFFICER	Jul 27 '26	Proposed Sale	261.99	772	202,256		Jul 27 03:36 PM
STEVEN CHAPMAN	OFFICER	Jul 27 '26	Proposed Sale	261.99	2,163	566,684		Jul 27 03:35 PM
MICHAEL BROPHY	OFFICER	Jul 27 '26	Proposed Sale	261.99	772	202,256		Jul 27 03:35 PM
Sheena Jonathan	CO-FOUNDER	Jul 15 '26	Sale	273.88	1,500	410,825	18,032	Jul 17 09:05 PM
Chapman Rowan E	Director	Jul 15 '26	Sale	274.82	135	37,101	4,663	Jul 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jul 13 '26	Sale	265.68	3,150	836,898	246,202	Jul 15 09:05 PM
ROWAN EMMA CHAPMAN	Director	Jul 15 '26	Proposed Sale	274.82	135	37,101		Jul 15 04:13 PM
Sheena Jonathan	Director	Jul 15 '26	Proposed Sale	275.22	1,500	412,830		Jul 15 10:10 AM
Sheena Jonathan	Director	Jul 13 '26	Proposed Sale	266.22	9,450	2,515,779		Jul 13 11:05 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jul 06 '26	Sale	280.00	1,000	280,000	4,000	Jul 08 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 01 '26	Sale	272.29	16,800	4,574,431	172,294	Jul 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 01 '26	Sale	272.90	3,000	818,710	134,643	Jul 06 09:05 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Jul 06 '26	Proposed Sale	280.00	1,000	280,000		Jul 06 04:56 PM
DANIEL RABINOWITZ	Officer	Jul 01 '26	Proposed Sale	271.45	16,800	4,560,360		Jul 01 04:15 PM
SOLOMON MOSHKEVICH	Officer	Jul 01 '26	Proposed Sale	272.90	3,000	818,710		Jul 01 04:13 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jun 24 '26	Sale	251.65	33,600	8,455,355	189,094	Jun 26 09:05 PM
ROSENMAN HERM	Director	Jun 24 '26	Sale	250.00	16,530	4,132,500	4,250	Jun 26 09:05 PM
DANIEL RABINOWITZ	Officer	Jun 24 '26	Proposed Sale	234.76	33,600	7,887,936		Jun 24 04:36 PM
HERMAN ROSENMAN	Director	Jun 24 '26	Proposed Sale	250.00	16,530	4,132,500		Jun 24 04:21 PM
Sheena Jonathan	CO-FOUNDER	Jun 17 '26	Sale	219.87	1,500	329,810	18,782	Jun 22 09:05 PM
Chapman Rowan E	Director	Jun 16 '26	Sale	216.78	2,964	642,536	3,124	Jun 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 15 '26	Sale	211.14	3,150	665,087	249,352	Jun 17 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 15 '26	Sale	214.91	50,000	10,745,662	2,277,843	Jun 16 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 12 '26	Sale	214.03	50,000	10,701,645	2,327,843	Jun 16 09:35 PM
ROWAN EMMA CHAPMAN	Director	Jun 16 '26	Proposed Sale	216.78	2,964	642,536		Jun 16 04:02 PM
MATTHEW RABINOWITZ	Director	Jun 12 '26	Proposed Sale	219.23	100,000	21,923,000		Jun 12 04:42 PM
Marcus Gail Boxer	Director	Jun 05 '26	Option Exercise	22.83	11,000	251,130	17,183	Jun 09 09:05 PM
Marcus Gail Boxer	Director	Jun 05 '26	Sale	217.21	11,000	2,389,328	6,183	Jun 09 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jun 04 '26	Sale	221.03	41,124	9,089,776	108,743	Jun 05 09:05 PM
GAIL MARCUS	Director	Jun 05 '26	Proposed Sale	217.21	11,000	2,389,328		Jun 05 05:15 PM
STEVEN L CHAPMAN	Officer	Jun 04 '26	Proposed Sale	221.03	41,124	9,089,778		Jun 04 05:03 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jun 01 '26	Sale	218.43	3,000	655,295	137,643	Jun 03 09:05 PM
BOTHA ROELOF	Director	Jun 01 '26	Sale	220.31	78,000	17,184,092	1,076,198	Jun 03 04:40 PM
BV369 TRUST	Affiliate	Jun 01 '26	Proposed Sale	220.31	78,000	17,184,094		Jun 01 04:12 PM
SOLOMON MOSHKEVICH	Officer	Jun 01 '26	Proposed Sale	218.43	3,000	655,295		Jun 01 04:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 26 '26	Sale	202.84	1,652	335,091	140,643	May 28 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	May 26 '26	Sale	202.84	1,438	291,684	185,782	May 28 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 08 '26	Sale	208.60	3,150	657,104	252,502	May 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 13 '26	Sale	201.56	1,500	302,347	19,532	May 15 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 05 '26	Sale	213.77	6,986	1,493,363	2,376,402	May 06 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 04 '26	Sale	206.16	722	148,848	2,382,440	May 06 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 04 '26	Sale	210.49	482	101,456	57,496	May 05 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 01 '26	Sale	206.16	313	64,528	57,978	May 05 09:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your Finviz experience